Caliper Cuts '06 Outlook as SEC Review Delays Xenogen Acquisition

Jul 13, 2006

NEW YORK (GenomeWeb News) - Caliper Life Sciences lowered its previously announced financial outlook for the year due to an SEC review of the company's plan to buy Xenogen, which delayed the acquisition, the company said today.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Last of the Northern White Rhinoceroses, Sequenced

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Thanks for the Stress, Dad

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

DNA Phenotyping Allowed in Bavaria

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

This Week in Science

In Science this week: gut microbiome influences liver cancer growth, spread; and more.

Main menu